Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

durvalumab × CNS × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 77 Gastrointestinal 57 Genitourinary 22 Breast 11 Gynecologic 8 Sarcoma 6 Head & Neck 6 Other solid neoplasm 5 Tumor-Agnostic 3 Endocrine 2 Dermatologic 2 Other hematologic neoplasm 1 Lymphoid 1 CNS 1

Conditions

Interventions

Temozolomide 76 Magnetic Resonance Spectroscopy 75 Specimen Handling 49 Radiotherapy 44 Cyclophosphamide 36 Radiosurgery 31 pembrolizumab 28 Radiation 24 Bevacizumab 21 Nivolumab 20 Biopsy 20 Vincristine 18 Carboplatin 18 fludarabine 17 Irinotecan 16 dinutuximab 14 Etoposide 14 Surgical Procedures, Operative 12 Lomustine 12 Ipilimumab 12 Cisplatin 12 abemaciclib 11 Topotecan 11 trametinib 10 Granulocyte-Macrophage Colony-Stimulating Factor 10 sargramostim 9 X-Rays 9 Melphalan 9 Blood Specimen Collection 9 AZD 6244 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02866747 2026-04-14

STERIMGLI

Institut Claudius Regaud

Phase 1/2 Completed

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡